Stockreport

Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates [Yahoo! Finance]

Neurogene Inc.  (NGNE) 
PDF Continues to expect to share additional interim clinical data from NGN-401 Phase 1/2 trial in the second half of 2025 Received PRIME designation for NGN-401 from the [Read more]